Lates News

Each AI fast news, Dongwu Securities issued a research report on March 26, giving a "buy" rating to Huitai Medical (688617.SH). The rating reasons mainly include: 1) steady growth of core products, with gross profit margins of main product lines increasing year-on-year; 2) issuing equity incentives to demonstrate long-term growth confidence; 3) smooth promotion of electrophysiology by 2025, further increasing market coverage of various product lines. (Daily Economic News)